Nanoparticle fabrication methods, systems, and materials for fabricating artificial red blood cells

Patent metadata

Field	Value
Publication number	US-9724305-B2
Application number	US-201615198081-A
Country	US
Kind code	B2
Filing date	Jun 30, 2016
Priority date	Jul 27, 2006
Publication date	Aug 8, 2017
Grant date	Aug 8, 2017

Abstract

A plurality of artificial red blood cell particles includes each particle of the plurality being substantially monodisperse and each particle having a largest common linear dimension of about 5 μm to about 10 μm. The particles can also have a modulus configured such that a particle of the plurality of particles can pass through a tube having an inner diameter of less than about 3 μm.

First claim

What is claimed is:

1. A synthetic particle, comprising:
a molded synthetic polymer particle having:
a largest linear dimension of between about 5 μm to about 10 μm; and,
a modulus of less than about 1 MPa, wherein the particle can pass through an opening of less than about 3 μm.

2. The particle of claim 1 , wherein the synthetic polymer comprises a biocompatible polymer.

3. The particle of claim 1 , wherein the synthetic polymer comprises poly(ethylene glycol) or poly(ethylene glycol) diacrylate.

4. The particle of claim 1 , wherein the particle further comprises a cargo selected from the group consisting of a therapeutic agent, a biologic, a diagnostic agent, hemoglobin, and an imaging agent.

5. The particle of claim 1 , wherein the opening is an orifice or an opening of a tube or a lumen.

6. The particle of claim 1 , wherein the particle further comprises an engineered shape characteristic comprising an arc or vertex imparted on the particle by the mold.

7. A drug delivery particle, comprising:
a molded synthetic polymer particle comprising a cargo and having:
a largest linear dimension less than about 10 μm; and,
a modulus of less than about 1 MPa, wherein the particle can pass through an opening of less than about 60% the largest linear dimension of the particle.

8. The drug delivery particle of claim 7 , wherein the particle can pass through an opening of less than about 37.5% the largest linear dimension of the particle.

9. The drug delivery particle of claim 7 , wherein the particle can pass through an opening of less than about 30% the largest linear dimension of the particle.

10. The drug delivery particle of claim 7 , wherein the synthetic polymer comprises a biocompatible polymer.

11. The drug delivery particle of claim 7 , wherein the synthetic polymer comprises poly(ethylene glycol) or poly(ethylene glycol) diacrylate.

12. The drug delivery particle of claim 7 , wherein the cargo is selected from the group consisting of a therapeutic agent, a biologic, a diagnostic agent, hemoglobin, and an imaging agent.

13. The drug delivery particle of claim 7 , wherein the opening is an orifice or an opening of a tube or a lumen.

14. The drug delivery particle of claim 7 , wherein the particle further comprises an engineered shape characteristic comprising an arc or vertex imparted on the particle by the mold.

15. A polymeric medical device, comprising:
a molded polymer having:
a largest linear dimension less than about 10 μm; and,
a modulus of less than about 1 MPa, wherein the device can pass through an opening less than about 60% the largest linear dimension of the device.

16. The polymeric medical device of claim 15 , wherein the device can pass through an opening of less than about 37.5% the largest linear dimension of the device.

17. The polymeric medical device of claim 15 , wherein the synthetic polymer comprises poly(ethylene glycol) or poly(ethylene glycol) diacrylate.

18. The polymeric medical device of claim 15 , wherein the device further comprises a cargo selected from the group consisting of a therapeutic agent, a biologic, a diagnostic agent, hemoglobin, and an imaging agent.

19. The polymeric medical device of claim 15 , wherein the opening is an orifice or an opening of a tube or a lumen.

Assignees

• Univ North Carolina Chapel Hill

Inventors

• Desimone Joseph M
• Samulski Edward T

Classifications

• A61K9/1641 Primary

  obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers · CPC title

• Y10S514/832

  Cross-Sectional Technologies · mapped topic

• C08L71/02

  Polyalkylene oxides · CPC title

• A61K9/0026

  Blood substitute; Oxygen transporting formulations; Plasma extender · CPC title

• A61K35/18

  Erythrocytes (haemoglobin A61K38/42) · CPC title